Clinical Trials
24 trialsNCT06522360 2025-04-24
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03164694 2024-12-10
APPEAL
Sun Yat-sen University
Phase 2 Withdrawn
NCT03623776 2024-12-06
NAJSCR
Sun Yat-sen University
Phase 2 Withdrawn
NCT05364645 2024-07-09
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT03190239 2024-02-28
XQonc-007
Xinqiao Hospital of Chongqing
Phase 2 Withdrawn
NCT02531854 2023-12-19
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Advaxis, Inc.
Phase 2 Withdrawn
NCT05948462 2023-12-13
NSCLC
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT04989283 2023-09-26
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02607423 2023-05-25
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT03843853 2022-07-25
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Withdrawn
NCT04754815 2022-03-29
HFHS 21-01
Henry Ford Health System
Phase 2 Withdrawn
NCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02662634 2022-03-18
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
GU Research Network, LLC
Phase 2 Withdrawn
NCT04061590 2022-03-04
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT04470674 2022-03-03
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04262869 2021-10-27
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University
Phase 2 Withdrawn
NCT04611776 2021-06-16
CATHAYA
Hoffmann-La Roche
Phase 2 Withdrawn
NCT02947113 2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2 Withdrawn
NCT02296671 2016-03-08
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
Washington University School of Medicine
Phase 2 Withdrawn
NCT01928160 2015-07-13
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT01336543 2014-12-18
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
Louisiana State University Health Sciences Center Shreveport
Phase 2 Withdrawn
NCT02013453 2014-12-02
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01674738 2013-10-11
SELECT-A
Aktion Bronchialkarzinom e.V.
Phase 2 Withdrawn
NCT01105390 2013-08-02
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Withdrawn